OIPE
MAR 2 2 2002
JC13
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application No.	09/760,120
Filing Date:	January 12, 2001
First Named Inventor	Sarah S. Bacus
Group Art Unit	1641
Examiner Name	
Attorney Docket No.	01-033

RECEIVED
MAR 2 8 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
SS		6,165,734		~~Buckwald et al.~~ Garini et al.		
SS		5,998,151		~~Fisher et al~~ Johnston et al.		
SS		5,514,554		Sarah Bacus		
SS		5,202,931		Sarah Bacus		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T[6]
SS		WO	00/23799	A	Steven Smith			
SS		EP	0378 383		Univ. Arizona			
SS		WO	93 03741		Yeda Res. & Dev.			

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		~~Van Diest et al., Analytical Cellular Pathology, vol. 3, no. 4, 1991, pages 195-202.~~ Duplicate	
SS		Bacus et al., Archives of Pathology and Laboratory Medicine, vol. 114, no. 2, 1990, pages 164-169	
SS		Bacus et al., American Journal of Pathology, vol. 137, no.1, July 1990, pages 103-111	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO

OIPE
MAR 2 2 2002
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application No.	09/760,120
Filing Date:	January 12, 2001
First Named Inventor	Sarah S. Bacus
Group Art Unit	1641
Examiner Name	
Attorney Docket No.	01-033

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
SV		Van Diest et al., Analytical Cellular Pathology, vol. 3, no. 4, 1991, pages 195-202.	
SV		Muss et al., 1994, N. Engl. J. Med. 330:1260-66	
SV		Kraus et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:9193-97	
SV		Mendelsohn, 1990, Semin. Cancer Biol. 1:339-44	
SV		Hancock et al., 1991, Cancer Res. 51:4575-80	
SV		Peles et al., 1991, EMBO J. 10:2077-86	
~~SV~~		~~Peles et al., 1991, EMBO J. 10:2077-86~~ Duplicate	
SV		Arteaga et al., 1994, Cancer Res., 54:3758-65	
SV		Pietras et al., 1994, Oncogene 9:1829-38	
SV		Cobleigh et al., 1999, J. Clin. Oncol. 17:2639-48	
~~SV~~		~~DiGiovanna, 1999, PPO Updates: Princ. Practice Oncol. 13:1-9~~	
~~SV~~		~~Shak, 1999, Semin. Oncol. 26:71-77~~	
~~SV~~		~~Sliwkowski et al., 1999, Semin. Oncol. 26:60-70~~	
SV		Vincent et al., 2000, Cancer Chemother. Pharmacol. 45:231-38	
SV		Lowry et al., 1951, J. Biol. Chem. 193:265-275	

RECEIVED
MAR 2 8 2002
TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application No.	09/760,120
Filing Date:	January 12, 2001
First Named Inventor	Sarah S. Bacus
Group Art Unit	1641
Examiner Name	
Attorney Docket No.	01-033

OIPE JC53 APR 15 2002 PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900 APR 19 2002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
SB		6,165,734		~~Buckwald~~ et al. Garni et al.		
SB		5,998,151		~~Fisher et al~~ Johnston et al		
SB		5,514,554		Sarah Bacus		
SB		5,202,931		Sarah Bacus		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T[6]
SB		WO	00/23799	A	Steven Smith			
SB		EP	0378 383		Univ. Arizona			
SB		WO	93 03741		Yeda Res. & Dev.			

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]

Examiner Signature	Dwilene B. Babel	Date Considered	5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO				Complete if Known	
				Application No.	09/760,120
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date:	January 12, 2001
				First Named Inventor	Sarah S. Bacus
				Group Art Unit	1641
(use as many sheets as necessary)				Examiner Name	
Sheet	2	of	3	Attorney Docket No.	01-033

TECH CENTER 1600/2900

APR 19 2002

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
SB		Arteaga et al., 1994, Cancer Res., 54:3758-65	
SB		Bacus et al., "Potential use of Image Analysis for the Evaluation of Cellular Predicting Factors for Therapeutic Response in Breast Cancers", Analytical and Quantitative Cytology and Histology, vol. 19 no. 4, August 1997, pages 316-328.	
SB		Bacus et al., "HER-2/neu oncogene expression, DNA ploidy and proliferation index in breast cancer", Analytical and Quantitative Cytology and Histology", vol. 14, no. 6, 1992 pages 433-445.	
SB		Bacus et al., "HER-2/NEU Oncogene Expression and DNA Ploidy Analysis in Breast Cancer", American Journal of Pathology, vol. 114, no. 2, 1990, pages 164-169.	
SB		Bacus et al., "HER-2/Neu oncogene expression and proliferation in breast cancer", American Journal of Pathology, vol. 137, no. 1- July 1990.	
SB		Cobleigh et al., "Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease", 1999, J. Clin. Oncol. 17:2639-48.	
SB		Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines",1991, Cancer Res. 51:4575-80.	
SB		Kraus et al., "Isolation and Characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors", 1989, Proc. Natl. Acad. Sci. U.S.A. 86:9193-97.	
SB		Lowry et al., "Protein Measurement with the Folin Phenol Reagent", 1951, J. Biol. Chem. 193:265-275.	

Sarah S. Bacus 5/21/02

Substitute for form 1449A/PTO	Complete if Known

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3

Application No.	09/760,120
Filing Date:	January 12, 2001
First Named Inventor	Sarah S. Bacus
Group Art Unit	1641
Examiner Name	
Attorney Docket No.	01-033

APR 15 2002 PATENT & TRADEMARK OFFICE

TECH CENTER 600/2900 APR 19 2002

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	[2]
SS		Mendelsohn, "The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies" 1990, Semin. Cancer Biol. 1:339-44.	
SS		Muss et al., "c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer",1994, N. Engl. J. Med. 330:1260-66.	
SS		Peles et al., "Oncogenic Forms of the Neu/HER2 Tyrosine Kinase are Permanently Coupled to Phospholipase Cy", 1991, EMBO J. 10:2077-86.	
SS		Peles et al., "Isolation of the Neu/HER-2 Stimulatory Ligand: A 44 kd Glycoprotein That Induces Differentiation of Mammary Tumor Cells", 1992, Cell 69:205-16.	
SS		Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cell", 1994, Oncogene 9:1829-38.	
SS		Van Diest et al., "Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material", Analytical Cellular Pathology, vol. 3, no. 4, 1991, pages 195-202.	
SS		Vincent et al., "Anticancer efficacy of the Irreversible EGFr Tyrosine Kinase Inhibitor PD 0169414 Against Human Tumor Xenografts", 2000, Cancer Chemother. Pharmacol. 45:231-38.	

Examiner Signature	Josiane R. Gabel	Date Considered	5/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231